Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET

Company Participants

Jennifer Viera - Investor Relations

Jay Luly - President and Chief Executive Officer

Paul Mellett - Chief Financial Officer

Tara Kieffer - Senior Vice President of New Product Strategy and Development

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Jay Olson - Oppenheimer

Ed Arce - H.C. Wainwright

Eric Joseph - JPMorgan

Roy Buchanan - JMP Securities

Amy Li - Jefferies

Luke Herrmann - Baird

Nick Veltri - Leerink Partners.

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter Financial Results Conference Call. At this time, all participants are in a listen only mode. There will be a question-and-answer session at the end of prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal third quarter 2023 financial results was issued this afternoon and is available on our website.

Making formal remarks on today’s call are Dr. Jay Luly, President and Chief Executive Officer and Paul Mellett, our Chief Financial Officer; and Dr. Scott Rottinghaus, our Chief Medical Officer and Dr. Tara Kieffer, our Senior Vice President of New Product Strategy and Development will be available during the Q&A portion of the call.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements.

A description of these risks is in our most recent Form 10-Q and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I would now like to turn the call over to Dr. Jay Luly, President and CEO. Jay.

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. At Enanta, we are committed to our mission of being a leader in the development of groundbreaking therapeutics for viral infections. In this this quarter we made important strides to bring us closer to impactful inflection points and ultimately our goals.